Cadrenal Therapeutics, Inc. Common Stock – NASDAQ:CVKD

Add to watchlist

$13.99

-2.15

-13.37%

Market open

Closed in 3 minutes

+3408.58%

month

+3408.58%

quarter

+2901.86%

year

Market Cap	23.67M
Enterprise value	N/A

P/E	N/A
EV/Sales	N/A
EV/EBITDA	N/A
Price/Sales	N/A
Price/Book	N/A
PEG ratio	N/A
EPS	-0.35

Revenue	N/A
EBITDA	-5.05M
Income	-4.84M
Revenue Q/Q	N/A
Revenue Y/Y	N/A

Profit margin	0%
Oper. margin	0%
Gross margin	0%
EBIT margin	0%
EBITDA margin	N/A

Get more financial ratios!

Every financial ratio you might need
10 years history
Forward ratios (Analysts estimates)

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Cadrenal Therapeutics, Inc. Common Stock Stock Forecast

M Q Y

Last Year

$32

Potential upside: 128.73%

Analysts Price target
Financials & Ratios estimates

Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD): Profit margin
Jun 2023	0	-1.00M
Sep 2023	0	-1.03M
Dec 2023	2.76K	-1.14M	-41331.65%
Mar 2024	0	-1.66M

Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD): Earnings per share (EPS)
2024-03-11	-0.09	-0.05
2024-05-09	-0.07	-0.1

Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD): Debt to assets
Jun 2023	3559026	383.10K	10.76%
Sep 2023	9311618	565.79K	6.08%
Dec 2023	8519250	826.87K	9.71%
Mar 2024	7048431	856.31K	12.15%

Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD): Cash Flow
Jun 2023	-795.30K	-3.25K	-23.17K
Sep 2023	-627.77K	-1	6.50M
Dec 2023	-694.44K	1	-12.5K
Mar 2024	-1.83M	0	298

Cadrenal Therapeutics, Inc. Common Stock alternative data

Cadrenal Therapeutics, Inc. Common Stock
Employees

Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD): Employee count
Aug 2023	3
Sep 2023	3
Oct 2023	3
Nov 2023	3
Dec 2023	3
Jan 2024	3
Feb 2024	3
Mar 2024	4
Apr 2024	4
May 2024	4
Jun 2024	4
Jul 2024	4

Cadrenal Therapeutics, Inc. Common Stock
Hedge Funds Holdings Q1 2023

0.01% +0.01%

of CVKD is owned by hedge funds

3 +3

hedge funds hold CVKD stock

847 +847

shares is hold by hedge funds

CVKD hedge funds holdings changes

Cadrenal Therapeutics, Inc. Common Stock
Insider Trading

Cadrenal Therapeutics, Inc. Common Stock (NASDAQ:CVKD): Insider trades (number of shares)
Period	Buy	Sel
Mar 2023	30000	0
Sep 2023	110000	0
Oct 2023	20000	0

Transaction	Date	Insider	Security	Shares	Price per share	Total value
Purchase	5 Oct 2023	MURPHY JOHN RAYMOND director director	Common Stock	2,669	$0.69	$1,842
Purchase	4 Oct 2023	MURPHY JOHN RAYMOND director director	Common Stock	17,331	$0.7	$12,132
Purchase	5 Sep 2023	PHAM QUANG X director, 10 percent owner, officer: CEO and .. director, 10 percent owner, off..	Common Stock	20,000	$0.9	$17,980
Purchase	5 Sep 2023	PHAM QUANG X director, 10 percent owner, officer: CEO and .. director, 10 percent owner, off..	Common Stock	20,000	$0.91	$18,200
Purchase	1 Sep 2023	PHAM QUANG X director, 10 percent owner, officer: CEO and .. director, 10 percent owner, off..	Common Stock	10,000	$0.84	$8,430
Purchase	1 Sep 2023	PHAM QUANG X director, 10 percent owner, officer: CEO and .. director, 10 percent owner, off..	Common Stock	10,000	$0.92	$9,170
Purchase	1 Sep 2023	PHAM QUANG X director, 10 percent owner, officer: CEO and .. director, 10 percent owner, off..	Common Stock	20,000	$0.92	$18,440
Purchase	1 Sep 2023	PHAM QUANG X director, 10 percent owner, officer: CEO and .. director, 10 percent owner, off..	Common Stock	20,000	$0.93	$18,580
Purchase	1 Sep 2023	PHAM QUANG X director, 10 percent owner, officer: CEO and .. director, 10 percent owner, off..	Common Stock	10,000	$0.93	$9,320
Purchase	21 Mar 2023	MURPHY JOHN RAYMOND director director	Common Stock	10,000	$1.39	$13,900

CVKD insider trading transactions

Cadrenal Therapeutics, Inc. Common Stock
Latest News

Tuesday, 19 November 2024
09:00	Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook	prnewswire.com
Tuesday, 12 November 2024
09:00	CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS	prnewswire.com
Thursday, 7 November 2024
09:00	CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE	prnewswire.com
Friday, 1 November 2024
20:00	Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds	prnewswire.com
Thursday, 24 October 2024
09:00	Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility	prnewswire.com
Wednesday, 23 October 2024
09:00	CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM	prnewswire.com
Monday, 23 September 2024
16:15	Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference	prnewswire.com
Thursday, 22 August 2024
09:00	Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients	prnewswire.com
Tuesday, 20 August 2024
09:00	Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients	prnewswire.com
Wednesday, 14 August 2024
09:00	Cadrenal Therapeutics to Present at Upcoming Investor Conferences	prnewswire.com
Wednesday, 7 August 2024
16:05	Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update	prnewswire.com
Tuesday, 6 August 2024
09:00	Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs	prnewswire.com
Wednesday, 17 July 2024
09:00	Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024	prnewswire.com
Tuesday, 11 June 2024
16:15	Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024	prnewswire.com
Monday, 3 June 2024
09:00	Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients	prnewswire.com
Thursday, 23 May 2024
09:00	Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024	prnewswire.com
Thursday, 9 May 2024
09:00	Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update	prnewswire.com
Thursday, 11 April 2024
16:30	Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024	prnewswire.com
Tuesday, 9 April 2024
09:00	Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts	prnewswire.com
Monday, 11 March 2024
09:00	Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update	prnewswire.com
Monday, 26 February 2024
09:00	Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference	prnewswire.com
Thursday, 8 February 2024
09:00	Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial	prnewswire.com
Wednesday, 31 January 2024
09:00	Cadrenal Therapeutics Highlights Publication of Peer-Reviewed Article Supporting Need for New Anticoagulation Therapy for Patients with Certain Medical Conditions	prnewswire.com
Wednesday, 24 January 2024
09:00	Cadrenal Therapeutics to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024	prnewswire.com
Thursday, 4 January 2024
09:00	Cadrenal Therapeutics to Present at the Biotech Showcase on January 8, 2024 Alongside the J.P. Morgan Annual Healthcare Conference	prnewswire.com
Tuesday, 19 December 2023
09:00	Noble Capital Markets Initiates Coverage on Cadrenal Therapeutics with Outperform Rating and US$4.00 Price Target	prnewswire.com
Tuesday, 12 December 2023
09:00	Cadrenal Therapeutics Engages The Sage Group to Advance Tecarfarin's Late-Stage Development and Commercialization	prnewswire.com
Thursday, 30 November 2023
16:15	Cadrenal Therapeutics to Present at the NobleCon 19 Conference on December 4, 2023	prnewswire.com
Thursday, 9 November 2023
09:00	Cadrenal Therapeutics Provides Third Quarter 2023 Corporate Update	prnewswire.com
Monday, 9 October 2023
16:15	Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2023 Investor Conference	PRNewsWire

Frequently Asked Questions (FAQ)

What's the price of Cadrenal Therapeutics, Inc. Common Stock stock today?

One share of Cadrenal Therapeutics, Inc. Common Stock stock can currently be purchased for approximately $13.99.
When is Cadrenal Therapeutics, Inc. Common Stock's next earnings date?

Unfortunately, Cadrenal Therapeutics, Inc. Common Stock's (CVKD) next earnings date is currently unknown.
Does Cadrenal Therapeutics, Inc. Common Stock pay dividends?

No, Cadrenal Therapeutics, Inc. Common Stock does not pay dividends.
How much money does Cadrenal Therapeutics, Inc. Common Stock make?

Cadrenal Therapeutics, Inc. Common Stock has a market capitalization of 23.67M. Cadrenal Therapeutics, Inc. Common Stock made a loss 8.36M US dollars in net income (profit) last year or -$0.1 on an earnings per share basis.
What is Cadrenal Therapeutics, Inc. Common Stock's stock symbol?

Cadrenal Therapeutics, Inc. Common Stock is traded on the NASDAQ under the ticker symbol "CVKD".
What is Cadrenal Therapeutics, Inc. Common Stock's primary industry?

Company operates in the Healthcare sector and Biotechnology industry.
How do i buy shares of Cadrenal Therapeutics, Inc. Common Stock?

Shares of Cadrenal Therapeutics, Inc. Common Stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
How many employees does Cadrenal Therapeutics, Inc. Common Stock have?

As Jul 2024, Cadrenal Therapeutics, Inc. Common Stock employs 4 workers.
When Cadrenal Therapeutics, Inc. Common Stock went public?

Cadrenal Therapeutics, Inc. Common Stock is publicly traded company for more then 2 years since IPO on 20 Jan 2023.
What is Cadrenal Therapeutics, Inc. Common Stock's official website?

The official website for Cadrenal Therapeutics, Inc. Common Stock is cadrenal.com.
Where are Cadrenal Therapeutics, Inc. Common Stock's headquarters?

Cadrenal Therapeutics, Inc. Common Stock is headquartered at 822 A1A North, Ponte Vedra, FL.
How can i contact Cadrenal Therapeutics, Inc. Common Stock?

Cadrenal Therapeutics, Inc. Common Stock's mailing address is 822 A1A North, Ponte Vedra, FL and company can be reached via phone at +90 43000701.
What is Cadrenal Therapeutics, Inc. Common Stock stock forecast & price target?

Based on 1 Wall Street analysts` predicted price targets for Cadrenal Therapeutics, Inc. Common Stock in the last 12 months, the avarage price target is $32. The average price target represents a 128.73% change from the last price of $13.99.

Cadrenal Therapeutics, Inc. Common Stock

cadrenal.com

Exchange:

NASDAQ

Full time employees:

Industry:

Biotechnology

Sector:

Healthcare

Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel therapy with orphan drug indication for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

+90 43000701

822 A1A North
Ponte Vedra, FL 32082

CIK: 0001937993
ISIN: US1276361086
: